Adaptimmune to Participate in Upcoming Investor Co

PHILADELPHIA and OXFORD, U.K., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Adaptimmune’s Chief Financial Officer, will present at the Leerink 6 ^th Annual Global Healthcare Conference on Wednesday February 15, 2017 at 1:00 PM EST (6:00 PM BST). The conference is being held at the Lotte New York Palace Hotel. Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com  and available for a period of 30 days following the conference.

About Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR ^® (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com

Adaptimmune Contacts Investor Relations Will Roberts T:  (215) 825-9306  E: will.roberts@adaptimmune.com Juli P. Miller, Ph.D. T: (215) 825-9310 E: juli.miller@adaptimmune.com Media Relations Margaret Henry T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com